Stay updated with breaking news from Agent Capital. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Startup Star Therapeutics will use the Series B funding to support clinical development of a drug candidate for von Willebrand disease, a bleeding disorder. The capital will also support the formation of new biotech subsidiaries developing antibodies with therapeutic applications in hematology and immunology.
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
Orbital’s $270 million Series A and MiNA’s Therapeutics’ collaboration with BioMarin Pharmaceutical bring RNA medicines closer to treating human disease.
The Cambridge startup’s successful first fund-raising round defies the biotech industry’s slump.
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!